GlassScriptPhysician profile
Laura C Bush
NPI 1548541550
$1,331.92
in general payments reported to CMS, 2019-2025
12 companies · $59.59 in 2025
The $59.59 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.25 · 2022: $368 · 2023: $708 · 2024: $185 · 2025: $59.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $316.61 | 2022-2023 | Epclusa |
| Abbvie INC. | $309.74 | 2022-2023 | |
| Amgen INC. | $240.88 | 2023 | Repatha |
| Leo Pharma INC. | $184.64 | 2024-2025 | Adbry |
| Merck Sharp & Dohme LLC | $91.36 | 2022 | |
| Inspire Medical Systems, INC. | $87.81 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $33.63 | 2024 | |
| Organon LLC | $17.99 | 2022 | |
| Fidia Pharma USA INC. | $17.25 | 2024 | Hymovis, Hyalgan, Triluron |
| Abbott Laboratories | $11.86 | 2022 | |
| Amarin Pharma, INC. | $11.25 | 2021 | |
| Kerecis Limited | $8.90 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.